Top emerging biotech hubs in 2026

When it comes to centers for biotech innovation and expansion, well-established locations such as Boston and South San Francisco have long dominated the field. But in the last few years, an array of other cities have emerged to stake their claim by offering government incentives, new developments, a lower cost of living and other advantages.

These regions hope to ride the wave of the life sciences industry’s increased prominence since the pandemic. That attention has helped spark a global real estate boom, with more than 35 million square feet of lab and R&D space under construction in 2024, according to a report from real estate firm CBRE last year. READ MORE

Quarterly biotech funding continues upward in Q2 of 2026 trend with 4th straight quarter of growth

Part one: the COVID boom, then a long winter. During COVID, biotech funding shot up to $48.2 billion in one quarter (2Q20). Then it slid downhill for two years as things cooled off. By late 2022, funding had dropped all the way to $10.9 billion a quarter. People started calling this stretch the "biotech winter."

Part two: a fake spring. In January 2024, investors suddenly got excited about biotech again. Everyone who had been waiting to raise money for two years tried to do it at the same time. Funding jumped to $47.2 billion in one quarter, almost as high as the COVID peak. It wasn't one giant deal. It was just a lot of companies rushing through the door at once. READ MORE

Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.

The data come from J.P. Morgan’s first-quarter biopharma licensing and venture report (PDF). Analysts tracked 50 seed and series A investments collectively worth $2.3 billion over the first three months of 2026. The data reverse the encouraging trend seen in the first quarter of 2025, when J.P. Morgan reported (PDF) that the number of investments rose to 60 and their combined value reached $3.7 billion.  READ MORE